|Bid||122.39 x 800|
|Ask||124.95 x 900|
|Day's Range||121.86 - 124.77|
|52 Week Range||102.10 - 149.34|
|PE Ratio (TTM)||53.56|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.79|
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.
The 17-story office at 121 Seaport Blvd. will be the future headquarters of industrial software company PTC, which is relocating from Needham, and Alexion Pharmaceuticals, which is relocating from New Haven, Connecticut.
Alexion surprised Wall Street on Tuesday when it asked the FDA for an expedited review of its newest rare-disease drug, ALXN1210.
Alexion Pharmaceuticals, Inc. (ALXN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). “This first regulatory submission is an important step toward our goal of establishing ALXN1210 as the new standard of care for patients with PNH, building on 10 years of proven efficacy and safety with Soliris®, and 25 years of leadership in complement biology,” said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion.
Earlier this year, Oppenheimer's Hartaj Singh argued that earnings expectations were too high for big biotech companies heading into the first-quarter reporting season. Ahead of the reports, due out in mid-July, Singh argues that fundamentals for large-cap biotech, as well as sector sentiment are "slowly but surely improving," leading him to believe that the stocks could outperform, led by Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN), and Vertex Pharmaceuticals (VRTX). For Gilead, he's upbeat about a more stable pricing environment for hepatitis C treatments, while investors are getting more interested in the company's "budding" immunology and nonalcoholic steatohepatitis (NASH) franchises, setting up an attractive risk-reward profile going into the second quarter. Alexion reported "stellar" first-quarter earnings, and Singh sees another strong quarter ahead, and he wonders "when the Street will start giving management credit for relentless execution." Vertex is one of his favorite large-cap biotechs, and he sees a good report ahead, along with an update about the progress of its cystic-fibrosis drugs.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for presentation during the Late-Breaking Oral Session (at 11:45 a.m. CET) on Sunday, June 17, 2018 at the Annual Conference of the European Hematology Association (EHA) in Stockholm, Sweden. “We are very excited about EHA’s recognition of the robustness and importance of these data in complement inhibitor treatment-naïve patients.
LONDON, UK / ACCESSWIRE / June 13, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On June 11, 2018, the Company announced that it has signed a partnership deal with Complement Pharma to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. Active-Investors.com is currently working on the research report for Unity Biotechnology, Inc. (NASDAQ: UBX), which also belongs to the Healthcare sector as the Company Alexion Pharma.
Alexion Pharmaceuticals, Inc. (ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation, and has the potential to treat a variety of central nervous system disorders. Under the terms of the agreement, Alexion will provide Complement Pharma with up to € 14 million in milestone-dependent payments through Phase 1b development.
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).
Alexion Pharmaceuticals will likely keep 75% of its Soliris market in the U.S. even as rivals like Amgen try to copy the blockbuster drug, an analyst said Tuesday in a bullish note.
Alexion Pharmaceuticals today announced that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 12, 2018 at 11:20 a.m., PDT.
The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On May 25, 2018, the Company announced that its offer, through a wholly owned subsidiary, for the shares in Sweden-based Wilson Therapeutics has been accepted by shareholders, representing 97.7% of the total number of shares and votes in Wilson Therapeutics. Active-Investors.com is currently working on the research report for CEL-SCI Corporation (NYSE AMER: CVM), which also belongs to the Healthcare sector as the Company Alexion Pharma.
Incyte Corporation (INCY) is a biopharmaceutical company with headquarters in Wilmington, Delaware. Incyte’s business includes the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24: ArQule, Inc. (NASDAQ: ARQL ) Baxter ...
Alexion Pharmaceuticals, Inc. (ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7 percent of the total number of shares and votes in Wilson Therapeutics. “The acquisition of Wilson Therapeutics is a key first step in rebuilding our pipeline,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. In order to give Wilson Therapeutics’ shareholders additional time to accept the offer, Alexion has extended the acceptance period until June 8, 2018.
Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.
Since the start of 2018, Alexion Pharmaceuticals (ALXN) has fallen -2.5% to close at $121 as of May 16. Alexion Pharmaceuticals generated $300 million from operating activities in the first quarter of 2018 compared to $308 million in the first quarter of 2017. In the first quarter of 2018, Alexion Pharmaceuticals used $254.7 million in investing activities compared to $495.3 million in the first quarter of 2017.
Alexion Pharmaceuticals (ALXN) is conducting two Phase 3 clinical studies in patients suffering from aHUS (atypical hemolytic uremic syndrome), which leads to life-threatening damage to the kidney, brain, heart, and other critical organs. This plan entails a once-per-week dosing to PNH (paroxysmal nocturnal hemoglobinuria) patients to support registration in PNH as well as aHUS.